EX-32.1 5 exhibit321.htm EX-32.1
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Bicara Therapeutics Inc. (the “Company”) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:
1.The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2024 |  | By: | /s/ Claire Mazumdar
|  |  | Claire Mazumdar, Ph.D.
|  |  | Chief Executive Officer
|  |  | (Principal Executive Officer)
Date: November 12, 2024 |  | By: | /s/ Ivan Hyep
|  |  | Ivan Hyep
|  |  | Chief Financial Officer
|  |  | (Principal Financial and Accounting Officer)